Chimeric antigen receptor (CAR) T-cell therapy is a type of immunotherapy that modifies a patient’s immune system so it is more effective at finding and destroying cancer cells. CAR T-cell therapy helps T cells to focus their attention toward a substance in body which is harmful called an antigen. In the manufacturing of CAR T cells, a protein is added to the T cell’s surface to help them achieve this focus. This protein is called a chimeric antigen receptor. Cancer cells are known to hide from the normal immune system, but through CAR T-cell therapy, scientists are able to make T cells better equipped to find and kill some cancer cells. CAR T cell therapy involves removing T cells from the blood and introducing a new gene into those cells that enables them to recognize the cancer. Many types of cancer such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia (ALL) are treating with car T cell therapy in pediatric and young adults. Initially, U.S. Food and Drug Administration has approved car T cell therapy products for patients with adult B-cell non-Hodgkin’s lymphoma. As of March 2021, 5 CAR T-cell drugs have been approved by the U.S. Food and Drug Administration (FDA). As an emerging treatment strategy CAR-T therapy requires exploration to expand its clinical application, and further optimization. A continue focus on research around car T-cell therapy, including studying the use of current FDA-approved products for new indications and finding ways to make CAR T-cell therapy safer for patients is contribute to create opportunity in the market
Market Dynamics
Car T cell therapy becomes a remarkably promising treatment for cancer patients. Increasing incidence of cancer and failure of alternative treatments are some of the major factor that create the development of new technology, which contribute to drive the growth of market over the forecast period
Key features of the study:
- This report provides an in-depth analysis of the global Car T cell therapy market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global Car T cell therapy market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, strategies.
- Key companies covered as a part of this study include Novartis AG, McKinsey & Company, Bristol-Myers Squibb Company, Kite Pharma, Inc., Gilead Sciences, Inc., Amgen Inc., Juno Therapeutics, Eli Lilly and Company, Fate Therapeutics, Sorrento Therapeutics, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global Car T cell therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global car T cell therapy
Detailed Segmentation:
- Global Car T Cell Therapy Market, By Type :
- Abecma
- Breyanzi
- Kymriah
- Tecartus
- Yescarta
- Global Car T Cell Therapy Market, By Application:
- Global Car T Cell Therapy Market, By End-user:
- Hospitals
- Specialty Clinics
- Others
- Global Car T Cell Therapy Market, By Region:
- North America
- By Type
- Abecma
- Breyanzi
- Kymriah
- Tecartus
- Yescarta
- By Application
- By End User
- Hospitals
- Specialty Clinics
- Others
- By Country
- Latin America
- By Type
- Abecma
- Breyanzi
- Kymriah
- Tecartus
- Yescarta
- By Application
- By End User
- Hospitals
- Specialty Clinics
- Others
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Type
- Abecma
- Breyanzi
- Kymriah
- Tecartus
- Yescarta
- By Application
- By End User
- Hospitals
- Specialty Clinics
- Others
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Type
- Abecma
- Breyanzi
- Kymriah
- Tecartus
- Yescarta
- By Application
- By End User
- Hospitals
- Specialty Clinics
- Others
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Type
- Abecma
- Breyanzi
- Kymriah
- Tecartus
- Yescarta
- By Application
- By End User
- Hospitals
- Specialty Clinics
- Others
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Type
- Abecma
- Breyanzi
- Kymriah
- Tecartus
- Yescarta
- By Application
- By End User
- Hospitals
- Specialty Clinics
- Others
- By Country/Region
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Novartis AG*
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- McKinsey & Company
- Bristol-Myers Squibb Company
- Kite Pharma, Inc.
- Gilead Sciences, Inc.
- Amgen Inc.
- Juno Therapeutics
- Eli Lilly and Company
- Fate Therapeutics
- Sorrento Therapeutics, Inc.
“*” marked represents similar segmentation in other categories in the respective section.
Table of Content - Car T Cell Therapy Market
